Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas PDF Author: Andrés J. M. Ferreri
Publisher: Springer
ISBN: 3319751840
Category : Medical
Languages : en
Pages : 143

Get Book Here

Book Description
In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.

Resistance to Targeted Therapies in Lymphomas

Resistance to Targeted Therapies in Lymphomas PDF Author: Ana C. Xavier
Publisher: Springer Nature
ISBN: 3030244245
Category : Medical
Languages : en
Pages : 210

Get Book Here

Book Description
Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy. This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.

Pediatric Lymphomas

Pediatric Lymphomas PDF Author: Howard J. Weinstein
Publisher: Springer Science & Business Media
ISBN: 354068753X
Category : Medical
Languages : en
Pages : 296

Get Book Here

Book Description
This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology.

Safety of Biologics Therapy

Safety of Biologics Therapy PDF Author: Brian A. Baldo
Publisher: Springer
ISBN: 3319304720
Category : Medical
Languages : en
Pages : 623

Get Book Here

Book Description
This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences.

Bispecific Antibodies for T-Cell Based Immunotherapy

Bispecific Antibodies for T-Cell Based Immunotherapy PDF Author: Brian H. Santich
Publisher: Frontiers Media SA
ISBN: 2889664155
Category : Medical
Languages : en
Pages : 97

Get Book Here

Book Description
CK is affiliated with the Roche Innovation Center Zurich, holds stocks and has patents with Hoffmann-La Roche company. NKC reports receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc.; holding ownership interest/equity/options in Y-Mabs Therapeutics Inc., and in Abpro-Labs, and owning stock options in Eureka Therapeutics. NKC is the inventor of pending and issued patents filed by MSK, including hu3F8 and 8H9 licensed to Ymabs Therapeutics, beta-glucan to Biotec Pharmacon, and HER2 bispecific antibody to Abpro-labs. NKC is an advisory board member for Abpro-Labs and Eureka Therapeutics

The Peripheral T-Cell Lymphomas

The Peripheral T-Cell Lymphomas PDF Author: Owen A. O'Connor
Publisher: John Wiley & Sons
ISBN: 1119671310
Category : Medical
Languages : en
Pages : 434

Get Book Here

Book Description
THE PERIPHERAL T-CELL LYMPHOMAS Provides a comprehensive look at Peripheral T-Cell lymphomas, including the group’s unique geographic distribution, underlying genetics, and novel treatments Peripheral T-Cell lymphomas (PTCL) are a diverse group of lymphoid malignancies that develop from mature T cells and natural killer (NK) cells. PTCL represent 10-15% of all cases of non-Hodgkin lymphoma in the US, and up to 20-25% of cases in South America, Asia, and other regions around the world. The role of different etiologic factors and the variation of geographic distribution makes PTCL one of the most difficult types of cancer to understand and treat. For the first time in a single volume, The Peripheral T-Cell Lymphomas presents a comprehensive survey of this complex and rare group of blood cancers. Featuring contributions from an international team of leading authorities in the various aspects of PTCL, this authoritative text covers biology, epidemiology, classification, approved and emerging drugs, molecular genetics, and more. Detailed clinical chapters address diagnosis, prognosis, and treatment of each of the major PTCL subtypes identified in the 2018 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. This much-needed resource: Covers the biological basis, epidemiology, classification, and treatment of PTCL Discusses the future of the field, including global collaboration efforts and novel approaches to PCTL Explores the role of biologics in PTCL and autologous and allogeneic stem-cell transplantation Offers new insights on molecular pathogenesis, innovative therapeutics, and novel drug combinations Features contributions from the Chairs The T-Cell Lymphoma Forum: the world’s largest meeting focused on PTCL Reflecting the unique epidemiology and genetic diversity of the PTCL, The Peripheral T-Cell Lymphomas is an indispensable source of data, insight, and references for the medical community, particularly oncologists and hematologists in both training and practice.

Immunological Surveillance

Immunological Surveillance PDF Author: Macfarlane Burnet
Publisher: Elsevier
ISBN: 1483159221
Category : Medical
Languages : en
Pages : 289

Get Book Here

Book Description
Immunological Surveillance

Lymphoma: Pathology, Diagnosis and Treatment

Lymphoma: Pathology, Diagnosis and Treatment PDF Author: Robert Marcus
Publisher: Cambridge University Press
ISBN: 9780521865449
Category : Medical
Languages : en
Pages : 296

Get Book Here

Book Description
Places the major advances which have occurred in the area of lymphoma into the context of daily clinical practice.

Pathological reactions of cytotoxic lymphoid cells as universal therapeutic targets in cancer and autoimmune disease

Pathological reactions of cytotoxic lymphoid cells as universal therapeutic targets in cancer and autoimmune disease PDF Author: Elizaveta Fasler-Kan
Publisher: Frontiers Media SA
ISBN: 2832523730
Category : Medical
Languages : en
Pages : 111

Get Book Here

Book Description


Immunotherapy in 2020

Immunotherapy in 2020 PDF Author: Andreas Radbruch
Publisher: Springer Science & Business Media
ISBN: 3540708510
Category : Medical
Languages : en
Pages : 116

Get Book Here

Book Description
This volume features contributions from participants of the ESRF symposium on Immunotherapy in 2020—Visions and Trends for Targeting Inflammatory Diseases held in Potsdam near Berlin, Germany, in October 2006. The symposium presentations covered the main mechanisms of immunoregulation.